[1] MERLO M,CANNATA A,GOBBO M,et al.Evolving concepts in dilated cardiomyopathy[J].Eur J Heart Fail,2018,20(2):228-239.
[2] ROSENBAUM A N,AGRE KE,PEREIRA N L.Genetics of dilated cardiomyopathy:practical implications for heart failure management[J].Nat Rev Cardiol,2020,17(5):286-297.
[3] 周红,娜日罕,荣钰,等.扩张型心肌病患者两种治疗方法前后microRNA-126和microRNA-30a水平表达的研究[J].现代检验医学杂志,2020,35(4):6-9.
[4] 孙振华,梁巍巍,管洪宇,等.微小核糖核酸miR-766通过靶向调控环腺苷酸活化交换蛋白1促进高糖培养下心肌细胞凋亡[J].中华糖尿病杂志,2018,10(8):515-520.
[5] 中华医学会心血管病学分会,中国心肌炎心肌病协作组.中国扩张型心肌病诊断和治疗指南[J].临床心血管病杂志,2018,34(5):421-434.
[6] 王华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[7] BOTTNER PC.Dilated cardiomyopathy and severe heart failure.An update for pediatricians[J].Arch Argent Pediatr,2018,116(3):421-428.
[8] BONNET D.Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure[J].J Am Coll Cardiol,2017,70(10):1262-1272.
[9] SEFEROVIC P M,POLOVINA M,BAUERSACHS J,et al.Heart failure in cardiomyopathies:a position paper from the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail,2019,21(5):553-576.
[10] PODZIMKOVA J,PALECEK T,KUCHYNKA P,et al.Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy[J].Herz,2019,44(4):347-353.
[11] 滑劲咏,曹巍,卢迎宏,等.抗心肌抗体联合C反应蛋白与扩张型心肌病并发室性心律失常的关系研究[J].中国循证心血管医学杂志,2020,12(5):554-557.
[12] 廉静,张爱菊,张燕.超敏C反应蛋白与扩张型心肌病患者炎症因子水平、心功能的相关性[J].心血管康复医学杂志,2018,27(6):642-645.
[13] TUAL-CHALOT S,STELLOS K.MicroRNA-based therapy of postmyocardial infarction heart failure[J].Hellenic J Cardiol,2021,62(2):149-151.
[14] 徐振宇,杨立明,李广平,等.慢性心力衰竭患者血清miR-133a、miR-133b水平与心功能和心肌重构的关系[J].山东医药,2018,58(4):82-84. |
2023, Vol. 40 
